Adagene Inc. announced positive clinical results from its Phase 2 dose expansion study of muzastotug (ADG126) in patients with microsatellite stable colorectal cancer, reporting a 33% overall response ...

New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.

The FDA granted fast track designation (FTD) to IBI3003, a first-in-class trispecific antibody, for the treatment of patients ...

Additional complete response (CR) observed in patient with multiple tumors Confirmed overall response rate (ORR) of 50% in patients with combined positive score (CPS) ≥1, including 50% ORR in patients ...

New findings from this investigational study build on the strength of RYBREVANT ® (amivantamab-vmjw) in non-small cell lung cancer and broadens its potential across additional solid tumors RARITAN, ...

Atezolizumab combined with R-GemOx shows favorable safety and efficacy in relapsed/refractory DLBCL, especially in transformed FL cases. The study reported a 59% overall response rate and a 33% ...

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

Verzenio showed promising efficacy in high-grade meningiomas with CDK pathway or NF2 alterations, achieving progression-free survival at six months in 14 of 24 patients. Patients with NF2 alterations ...

Equillium, Inc. (NASDAQ:EQ) released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host ...

Xervyteg demonstrated a 62% GI overall response rate at day 28, significantly exceeding historical controls, with durable responses and survival benefits over one year. The safety profile was ...